CHICAGO, June 3 (Reuters) - New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard ...

Merck & Co.’s Keytruda has long been viewed as a standard of care in metastatic non-small cell lung cancer (NSCLC). Now, the PD-1 king has scored the FDA’s permission to enter early-stage disease with ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. Merck has ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) -The U.S. Food ...

Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with Keytruda to treat non-small cell lung ...

The Food and Drug Administration approved a Keytruda regimen to be administered before and after surgery for patients with stage 2, 3A or 3B non-small cell lung cancer. The Food and Drug ...

Acceptance based on results from the Phase 3 KEYNOTE-091 trial, the seventh positive pivotal study evaluating a KEYTRUDA-based regimen in earlier stages of cancer The study has dual primary endpoints ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 ...

Moderna's buzzy cancer vaccine partnership with Merck will soon take a leap into lung cancer, after recent clinical data showed the shot—alongside Merck's blockbuster Keytruda—significantly reduced ...

(Reuters) -The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can ...